Jalil JE, Lavandero S, Chiong M, et al. Rho/Rho-kinase signal transduction pathway in cardiovascular disease and cardiovascular remodeling. Rev Esp Cardiol 2005; 58: 951-61.
Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-75.
Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007; 28: 296-302.
Hata T, Soga J, Hidaka T, et al. Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens 2011; 29: 373-9.
Gabrielli L, Winter JL, Godoy I, et al. Increased Rho kinase activity in hypertensive patients with left ventricular hypertrophy. Am J Hypertens 2014; 27: 838-45.
Carbone ML, Bregeon J, Devos N, et al. Angiotensin II activates the RhoA exchange factor Arhgef1 in humans. Hypertension 2015; 65: 1273-8.
Ravarotto V, Pagnin E, Maiolino G, et al. The blocking of angiotensin II type 1receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling. J Renin Angiotensin Aldosterone Syst 2015; 16: 1245-50.
Rawlings R, Nohria A, Liu PY, et al. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol 2009; 103: 437-41.
Nohria A, Prsic A, Liu PY, et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 2009; 205: 517-21.
Ocaranza MP, Gabrielli L, Mora I, et al. Markedly increased Rho-kinase activity in circulating leukocytes in patients with chronic heart failure. Am Heart J 2011; 161: 931-7.
Ocaranza MP, Fierro C, Jalil JE, et al. Rho kinase activation in circulating leukocytes is related to hypertensive myocardial remodeling. Clin Sci (Lond) 2018; 132: 1837-53.
Fujimura N, Noma K, Hata T, et al. Mineralocorticoid receptor eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clin Pharmacol Ther 2012; 91: 289-97.
Qiao YN, He WQ, Chen CP, et al. Myosin phosphatase target subunit1(MYPT1) regulates the contraction and relaxation of vascular smooth muscle and maintains blood pressure. J Biol Chem 2014; 289: 22512-23.
Hata T, Goto C, Soga J, et al. Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis 2011; 214: 117-21.
Fierro C, Novoa U, Gonzalez V, et al. Simultaneous Rho kinase inhibition in circulating leukocytes and in cardiovascular tissue in rats with high angiotensin converting enzyme levels. Int J Cardiol 2016; 215: 309-17.
Kajikawa M, Noma K, Maruhashi T, et al. Rho-associated kinase activity is a predictor of cardiovascular outcomes. Hypertension 2014; 63: 856-64.